Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T
| العنوان: | Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T |
|---|---|
| المؤلفون: | Ludmila Manzuk, Sergei Varlamov, Anton Snegovoy, Ludmila Gurina, Sufia Safina, Ilya Varlamov, Ilya Tsimafeyeu |
| المصدر: | Onkourologiâ, Vol 11, Iss 2, Pp 34-39 (2015) |
| بيانات النشر: | Springer Science and Business Media LLC, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Male, Cancer Research, medicine.medical_specialty, Bevacizumab, Urology, Alpha interferon, Antineoplastic Agents, resistance to anti-vegf therapy, metastatic renal cell carcinoma, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Renal cell carcinoma, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Pharmacology (medical), Everolimus, Prospective Studies, Neoplasm Metastasis, Adverse effect, Carcinoma, Renal Cell, Aged, Pneumonitis, business.industry, TOR Serine-Threonine Kinases, Cancer, interferon, Middle Aged, medicine.disease, Kidney Neoplasms, Surgery, Vascular endothelial growth factor, Treatment Outcome, Oncology, chemistry, Nephrology, Medicine, Female, business, medicine.drug |
| الوصف: | Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR) recommended for patients with metastatic renal cell carcinoma (mRCC) who progressed on previous vascular endothelial growth factor (VEGF) receptor-tyrosine kinase inhibitor therapy. Efficacy of everolimus in patients who progressed on anti-VEGF monoclonal antibody bevacizumab is unknown. We did a multicenter prospective trial of everolimus in patients with mRCC whose disease had progressed on bevacizumab ± interferon alpha (IFN). Patients with clear-cell mRCC which had progressed on bevacizumab ± IFN received everolimus 10 mg once daily. The primary end point was the proportion of patients remaining progression-free for 56 days, and a two-stage Simon design was used, with 80 % power and an alpha risk of 5 %. This study is registered with ClinicalTrials.gov, number NCT02056587. From December 2011 to October 2013, a total of 37 patients (28 M, 9 F) were enrolled. Median age was 60.5 years (range 41-66), 11 % had Eastern Cooperative Oncology Group Performance Status (ECOG PS) > 2, and Memorial Sloan-Kettering Cancer Center (MSKCC) favorable/intermediate risk was 38/62 %. Five (14 %) patients had a confirmed partial response and 26 (70 %) patients had a stable disease. Median progression-free survival was 11.5 months (95 % CI, 8.8–14.2). Median overall survival was not reached. No grade 3 or 4 treatment-related toxicities were observed. The most common grade 2 adverse events were fatigue (19 %) and pneumonitis (8 %). Everolimus demonstrated a favorable toxicity profile and promising anti-tumor activity as a second-line therapy in metastatic renal cell carcinoma (RCC) patients previously treated with bevacizumab ± IFN. |
| تدمد: | 1776-260X 1776-2596 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839c407084fb09cbba11821e82b77f2e https://doi.org/10.1007/s11523-014-0347-4 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....839c407084fb09cbba11821e82b77f2e |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 1776260X 17762596 |
|---|